| Canagliflozin (Can)/ Metformin HCl (Met) |
Tablet (Extended Release) |
Met: I (Basket, 40 mesh): Can: I (Basket, 10 mesh [with option of tablet holder]) |
Met: 100: Can:100 |
Met: Simulated Gastric Fluid [SGF] without enzyme, pH 1.2; Can: 0.1% (w/v) polysorbate 20 in 0.05 M sodium phosphate buffer pH 6.8 ( 50 mg); 0.2% (w/v) polysorbate 20 in 0.05 M sodium phosphate buffer pH 6.8 (150 mg) |
Met: 900: Can: 900 |
Met: 1, 2, 4, 6, 8 10 and 12 hours: Can: 10, 15, 20, 30, 45 and 60 minutes; |
2016/12/22 |
| Canagliflozin/Metformin HCl |
Tablet |
II (Paddle) |
Canagliflozin: 75; Metformin: 50 |
Canagliflozin (50 mg): 0.025 %
Polysorbate 20; Canagliflozin (150 mg):0.075 %
Polysorbate 20; Metformin: Phosphate
buffer, pH 6.8 |
Canagliflozin (50 mg): 900; Canagliflozin (150 mg): 900 ; Metformin: 1000 |
Canagliflozin: 10, 15, 20, 30 and 45; Metformin: 5, 10, 15, 20 and 30 |
2015/05/28 |
| Candesartan Cilexetil (16 mg, 8 mg and 4 mg) |
Tablet |
II (Paddle) |
50 |
0.35% Polysorbate 20 in 0.05 M Phosphate Buffer, pH 6.5 |
900 |
10, 20, 30, 45 and 60 |
2007/06/20 |
| Candesartan Cilexetil (32 mg) |
Tablet |
II (Paddle) |
50 |
0.70% Polysorbate 20 in 0.05 M Phosphate Buffer, pH 6.5 |
900 |
10, 20, 30, 45 and 60 |
2007/06/20 |
| Candesartan Cilexetil/Hydrochlorothiazide (16/12.5 mg) |
Tablet |
II (Paddle) |
50 |
0.35% Polysorbate 20 in phosphate buffer pH 6.5 |
900 |
10, 20, 30, 45 and 60 |
2010/01/29 |
| Candesartan Cilexetil/Hydrochlorothiazide (32/12.5 mg and 32/25 mg) |
Tablet |
II (Paddle) |
50 |
0.70% Polysorbate 20 in phosphate buffer pH 6.5 |
900 |
15, 20, 30, 45 and 60 |
2010/01/29 |
| Capecitabine |
Tablet |
|
|
Refer to FDA's Dissolution Guidance, 2018 |
|
|
2020/07/02 |
| Capivasertib |
Tablet |
II (Paddle) |
60 |
Simulated Gastric Fluid without enzyme, pH 1.2 |
900 |
10, 15, 20, 30 and 45 |
2025/02/24 |
| Capmatinib HCl |
Tablet |
I (Basket) |
75 |
0.01N HCl (degassed) |
900 |
5, 10, 15, 20, 30 and 45 |
2022/05/12 |
| Captopril |
Tablet |
|
|
Refer to FDA's Dissolution Guidance, 2018 |
|
|
2020/07/02 |
| Carbamazepine |
Capsule (Extended Release) |
II (Paddle) |
75 |
First 4 hours: Dilute Acid, pH 1.1. After 4 hours: Phosphate Buffer, pH 7.5 with 0.1% sodium lauryl sulfate (SLS). |
First 4 h: 900. After 4 h: 900 |
1, 2, 4, 6, 8, 10 and 12 hours |
2011/09/01 |
| Carbamazepine |
Tablet |
|
|
Develop a dissolution method |
|
|
2024/01/03 |
| Carbamazepine |
Tablet (Chewable) |
|
|
Develop a dissolution method |
|
|
2023/09/15 |
| Carbamazepine |
Suspension |
|
|
Develop a dissolution method |
|
|
2023/09/15 |
| Carbamazepine |
Tablet (Extended Release) |
|
|
Develop a dissolution method |
|
|
2024/01/03 |
| Carbidopa |
Tablet |
|
|
Refer to FDA's Dissolution Guidance, 2018 |
|
|
2020/07/02 |
| Carbidopa/Entacapone/Levodopa |
Tablet |
I (Basket) |
Carbidopa and Levodopa: 50; Entacapone: 125 |
For both Carbidopa and Levodopa: 0.1 N HCl, For Entacapone: Phosphate buffer pH 5.5 |
Carbidopa and Levodopa: 750 ml. Entacapone: 900 ml |
10, 20, 30, 45 and 60 |
2007/01/03 |
| Carbidopa/Levodopa |
Tablet (Orally Disintegrating) |
II (Paddle) |
50 |
0.1 N HCl |
750 |
5, 10, 15, 30, and 45 |
2007/07/25 |
| Carbidopa/Levodopa |
Suspension (Enteral) |
II (Paddle) |
25 |
0.05 M Sodium Acetate Buffer, pH 4.5 |
500 |
5, 10, 15, 20, 30, 40 and 60 |
2016/10/20 |
| Carbidopa/Levodopa |
Tablet (Extended Release) |
II (Paddle) |
50 |
0.1 N HCl |
900 |
0.5, 0.75, 1, 1.5, 2, 2.5, 3 and 4 hours |
2013/08/15 |
请输入需要查询的英文药品通用名称，至少3个字符.